About
Pharnext
An advanced clinical-stage
biopharmaceutical company
Our company
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs.
Our drug Candidates
Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimer’s disease. Both of our lead assets originated from the Pleotherapy R&D approach.
Meet our team
Leadership team
Dr. David Horn Solomon
Chief Executive Officer
Burkhard Blank, MD
Chief Medical Officer
Valérie Worrall, MSc
Chief Financial Officer
Xavier Paoli, MSc
Chief Operating Officer
Antoine Gravelle
General Counsel
Raj Thota, MSc
Chief Manufacturing Officer and Head of CMC
Abhijit Pangu, MPharm
Head of Regulatory Affairs
Rupsa Dey, MSc
VP of Quality Assurance
Board of directors
Joshua Schafer
Chairman of the Board of Directors
James Kuo
Director
Lawrence Steinman
Director
David Horn Solomon
Director and Chief Executive Officer
Timeline
Explore our history since inception in 2007
2Q07
Pharnext is founded by Prof. Daniel Cohen and collaborators
4Q10
PXT3003: Launch of Phase 2 clinical trials in CMT1A
1Q13
PXT864: Launch of Phase 2 clinical trials in Alzheimer’s disease
2Q14
PXT3003: EMA and FDA orphan drug designation for CMT1A
4Q14
PXT3003: Positive Phase 2 results in CMT1A
4Q15
PXT3003: Launch of Phase 3 clinical trials in CMT1A
3Q16
Pharnext IPO on Alternext Stock Exchange in Paris
1Q17
R&D agreement with Galapagos to generate a new pipeline of synergistic drug combinations
2Q17
Strategic partnership with Tasly, a leading Chinese pharmaceutical group
4Q18
Pharnext and Vitaccess launch International CMT&Me Observational Study
4Q18
PXT3003: Positive topline results from pivotal Phase 3 trial in CMT1A
1Q19
PXT3003: FDA Fast Track designation for the treatment of CMT1A
1Q20
PXT3003: Encouraging preliminary data from open-label Phase 3 extension study in CMT1A
1Q20
PXT3003 granted “Promising Innovative Medicine” status by UK MHRA in CMT1A
1Q21
Launch of the PREMIER trial, Pivotal Phase 3 clinical study, in CMT1A